PH12016501023A1 - Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers - Google Patents
Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkersInfo
- Publication number
- PH12016501023A1 PH12016501023A1 PH12016501023A PH12016501023A PH12016501023A1 PH 12016501023 A1 PH12016501023 A1 PH 12016501023A1 PH 12016501023 A PH12016501023 A PH 12016501023A PH 12016501023 A PH12016501023 A PH 12016501023A PH 12016501023 A1 PH12016501023 A1 PH 12016501023A1
- Authority
- PH
- Philippines
- Prior art keywords
- biomarkers
- methods
- leanlidomide
- clinical sensitivity
- hematological cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12016501023A1 true PH12016501023A1 (en) | 2016-07-04 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016501023A PH12016501023A1 (en) | 2013-12-06 | 2016-05-31 | Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers |
Country Status (12)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| EP3207521B1 (en) * | 2014-10-17 | 2022-11-02 | Stichting Maastricht Radiation Oncology "Maastro Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| WO2017044793A1 (en) | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| AU2016326499A1 (en) * | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| WO2019065901A1 (ja) * | 2017-09-29 | 2019-04-04 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| AU2020372333B2 (en) * | 2019-10-21 | 2026-08-06 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158740A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2710196A1 (en) * | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016007179A (es) | 2016-09-08 |
| EP3077547A4 (en) | 2017-11-08 |
| IL245936A0 (en) | 2016-07-31 |
| CA2932266A1 (en) | 2015-06-11 |
| WO2015085160A3 (en) | 2015-07-30 |
| AU2014360316A1 (en) | 2016-06-16 |
| BR112016012792A2 (pt) | 2017-08-08 |
| KR20160090390A (ko) | 2016-07-29 |
| JP2017503481A (ja) | 2017-02-02 |
| WO2015085160A2 (en) | 2015-06-11 |
| EP3077547A2 (en) | 2016-10-12 |
| EA201691143A1 (ru) | 2016-11-30 |
| US20160312292A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015085160A3 (en) | Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers | |
| IL260774B (en) | Preparations containing 3cd19 x cd bispecific antibodies for the treatment of tumors of lymph node tissue and/or extra-lymph node lymphoma as a result of diffuse large b-cell lymphoma (dlbcl) | |
| SA521430032B1 (ar) | Vista أجسام مضادة لـ وأجزاء منها | |
| GB2467467B (en) | TAZ/WWTR1 for diagnosis and treatment of cancer | |
| MX2023004748A (es) | Un dispositivo para obtener una muestra de sangre. | |
| PH12017501368A1 (en) | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| CY1119763T1 (el) | Υποδοχεας ουρων για γυναικες | |
| EA201691361A1 (ru) | Антитела к lag-3 для лечения гематологических злокачественных опухолей | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| IL245766B (en) | Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc) | |
| TR201907737T4 (tr) | Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi. | |
| JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
| MY193895A (en) | Combination test for colorectal cancer | |
| EA201401201A1 (ru) | Способ | |
| SG10201806729VA (en) | Novel assay to detect human periostin | |
| EP3457138A3 (en) | Novel biomarkers for acute myeloid leukemia | |
| MX2018003697A (es) | Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. | |
| GB2465907A (en) | VHZ for diagnosis and treatment of cancer | |
| WO2014184684A3 (en) | Methods and biomarkers for detection of hematological cancers | |
| MX2015015023A (es) | Metodo para la determinacion de cobre libre. |